Description de l'entreprise
Spexis AG is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Spexis AG is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Spexis AG is based in Allschwil near Basel and is listed on the SIX Swiss Exchange.
Conseil d'administration & Conseil de surveillance
| PDG |
| Jeffrey D. Wager |
| Conseil d'administration |
| Hernan Levett, Stephan Wehselau, Juergen Froehlich |
| Conseil de surveillance |
| Jeffrey D. Wager, Dennis Ausiello, Bernard Bollag, Dr. Kuno Sommer, Robert Clarke , Dan Hartman |
Données de l'entreprise
| Nom: |
Spexis AG |
| Adresse: |
Hegenheimermattweg 125,CH-4123 Allschwil |
| Téléphone: |
+41-61-567-1600 |
| Fax: |
- |
| Courriel: |
info@polyphor.com
|
| Internet: |
https://www.polyphor.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
15/05/2018 |
Relations avec les investisseurs
| Nom: |
Hernan Levett |
| Téléphone IR: |
+41-61-567-1624 |
| IR-Fax: |
- |
| E-mail IR: |
IR@spexisbio.com
|
